| DB ID | MyCo_2679 |
| Title | Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients |
| Year | 2004 |
| PMID | 15352990 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | Neutropenic Cancer Patients and Haematological stem cell transplant recipients |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomamman |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Belzium |
| Cohort | From July 2001 to December 2002, we prospectively measured serum GM levels in a consecutive series of adult (>16 years of age) haemato-oncological patients who were considered to be at risk for developing IA. Eligible patients were receiving intensive chemotherapy for acute myeloid leukaemia or myelodysplasic syndrome with an expected neutropenia (<0Æ5 · 109/l) for at least 14 d or were undergoing myeloablative allogeneic HSCT. Patients with acute lymphoblastic leukaemia receiving high dose steroids as part of their remission–induction chemotherapy were also eligible. All patients were hospitalized in single reverse-isolation rooms in a unit equipped with high-efficiency particulate air filters until neutrophil recovery (>0Æ5 · 109/l). All patients received antifungal prophylaxis with itraconazole capsules 400 mg/d (serum levels were not measured) or fluconazole 400 mg p.o./i.v. in case of intolerance or inability to take oral itraconazole. Serum samples were taken at least twice weekly, starting at the beginning of cytoreductive therapy. |
| Cohort No. | None |
| Age Group | > 16 |
| P Value | None |
| Sensitivity | 0.965 |
| Specificity | 0.986 |
| Positive Predictive Value | 0.965 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | The incidence of angio-invasive aspergillosis (IA) has increased over the past decade, both in transplant recipients and in patients with haematological disorders. Aspergillus has now become the leading cause of infectious mortality in many haematology units and haematopoietic stem cell transplant (HSCT) centres in the US and Europe. In addition, the introduction of new modalities for HSCT, such as the use of non-myeloablative conditioning regimes and the use of novel immunosuppressive agents, will probably further contribute to the increasing incidence of fungal infections worldwide. Unfortunately, the overall mortality rate of IA remains high. Although the recent availability of voriconazole as a new agent for the primary treatment of IA represents an important therapeutic advance, approximately 50% of all patients will still be unresponsive to this intervention. In addition, for patients with profound persistent neutropenia or for those with uncontrolled graft-versus-host disease, IA often progresses irrespective of the type of antifungal therapy. |
| Technique | ELISA |
| Analysis Method | ELISA Based |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | ELISA |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
